Intraovarian regulation of gonadotropin-dependent folliculogenesis depends on notch receptor signaling pathways not involving Delta-like ligand 4 (Dll4) by Vuk P Jovanovic et al.
Jovanovic et al. Reproductive Biology and Endocrinology 2013, 11:43
http://www.rbej.com/content/11/1/43RESEARCH Open AccessIntraovarian regulation of gonadotropin-
dependent folliculogenesis depends on notch
receptor signaling pathways not involving
Delta-like ligand 4 (Dll4)
Vuk P Jovanovic1,2*†, Christopher M Sauer3†, Carrie J Shawber1, Raul Gomez4, Xing Wang1, Mark V Sauer1,
Jan Kitajewski1 and Ralf C Zimmermann1Abstract
Background: In-situ hybridisation studies demonstrate that Notch receptors and ligands are expressed in granulosa
cells (GCs) and in the theca layer vasculature of growing follicles. Notch signaling involves cell-to-cell interaction
mediated by transmembrane receptors and ligands. This signaling pathway may represent a novel intraovarian
regulator of gonadotropin-dependent follicular development to the preovulatory stage. We hypothesized that
blocking Notch pathways would disrupt follicular maturation in the mouse ovary.
Methods: Hypophysectomized CD21 female mice were administered pregnant mare serum gonadotropin (PMSG)
for 3 days to stimulate follicular development. In one experiment, a pan-notch inhibitor, compound E, was initiated
2 days prior to and throughout stimulation (n = 10), while in a second experiment, a humanized phage Dll4
blocking antibody, YW152F, was used (n = 5). After sacrifice, ovarian histology, serum estradiol levels and uterine
weights were compared to controls. The ovarian morphology was evaluated with hematoxylin/eosin staining and
immunohistochemistry was performed for Notch1, Notch2, Notch3, Notch4, Jagged1, Dll4, platelet endothelial cell
adhesion molecule (PECAM) and alpha-smooth muscle actin (α-SMA) detection.
Results: We localized specific Notch ligands and receptors in the following structures: Dll4 is specific to theca layer
endothelial cells (ECs); Notch1/Notch4 and Jagged1 are expressed in theca layer ECs and vascular smooth muscle
cells (VSMCs), whereas Notch3 is restricted to VSMCs; Notch2 is expressed mostly on GCs of small follicles.
Administration of a pan-Notch inhibitor, compound E, inhibits follicular development to the preovulatory stage
(8.5 preovulatory follicles in treatment vs. 3.4 preovulatory follicles in control, p < 0.01; average number per ovary)
with significant secondary effects on ovarian and uterine weight and estradiol secretion in a setting of uninhibited
vascular proliferation, but disorganized appearance of ECs and VSMCs. Inhibition of endothelial Notch1 function
through the inactivation of its ligand Dll4 with the blocking antibody YW152F induces mild disorganisation of
follicular vasculature, but has no significant effect on gonadotropin-dependent folliculogenesis.
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Conclusions: Our experiments suggest that the complete blockage of the Notch signaling pathway with
compound E impairs folliculogenesis and induces disruption of gonadotropin stimulated angiogenesis. It seems the
mechanism involves Notch1 and Notch3, specifically, causing the improper assembly of ECs and VSMCs in the
theca layer, although the potential role of non-angiogenic Notch signaling, such as Jagged2 to Notch2 in GCs,
remains to be elucidated.
Keywords: Notch, Dll4, Jagged, Folliculogenesis, Ovary, Gamma-secretase inhibitor, YW152FBackground
Major advances have been made in identifying and charac-
terizing the role of intraovarian regulators such as insulin
growth factor (IGF), epidermal growth factor (EGF), vas-
cular endothelial growth factor (VEGF), transforming
growth factors, anti-Müllerian hormone, bone morpho-
genetic protein with respect to gonadotropin-dependent
follicular development [1]. Despite these advances, our
understanding of how folliculogenesis is regulated is far
from complete, which suggests the existence of other un-
identified intraovarian regulators. In-situ hybridisation
studies have shown that vascular and non-vascular com-
ponents of the Notch pathway are localized to specific
structures in the ovary [2,3]. For example m-RNA of
Notch2, Notch3, and Jagged2 as well as downstream tar-
gets of Notch are highly expressed in the granulosa cells
(GCs) of developing follicles [2]. Vascular Notch m-RNA
(Notch1 and Notch4) was detected on blood vessels in the
theca layer of growing follicles [2], a finding later validated
by immunofluorescent studies [4]. Notch1 and the Notch
ligand Jagged1 can be detected on ECs as well as vascular
smooth muscle cells (VSMCs) [4]. The Notch ligands Dll1
and Dll3 are absent in the ovary [2], whereas the Notch1
ligand Dll4 was detected by in-situ hybridisation in ovarian
vasculature [2,5]. Results derived from expression analy-
sis suggest that Notch is a novel intraovarian regulator,
which regulates folliculogenesis through vascular and non-
vascular mechanisms [2,6]. It should be noted that Notch
would be unique among intraovarian regulators as Notch
ligands and receptors are single-pass transmembrane pro-
teins, requiring a juxtacrine (or contact-dependent) signal-
ing mechanism [3,7,8].
We hypothesized that blocking Notch pathways
would disrupt in-vivo folliculogenesis in our mouse
model by affecting vascular and non-vascular pathways.
This would confirm the effects on folliculogenesis de-
scribed in vitro [3], but also evaluate vascular growth
disruption surrounding maturing follicles. We used a
mouse model to perform functional studies using a
pan-Notch inhibitor, compound E, as well as a blocking
antibody (BAb) against the Notch1 ligand Dll4, located
exclusively on endothelial cells (ECs). As in-situ hybri-
disation studies can be discrepant with localisation of
the corresponding protein, we performed immuno-fluorescence with antibodies to Notch2, Notch3, and
Dll4.
Methods
The study was reviewed and approved by the Institutional
Review Board and the Institutional Animal Care Commit-
tee of the Columbia University Medical Center.
Animal model
CD21 female mice (Charles River, Wilmington, MA,
USA), hypophysectomized before 22 days of life, were
used for all experiments. Insignificant weight gain (< 2 g
over 8 days after arrival) and low estrogenic state vaginal
smears verified that the surgery had been successful in
arresting follicular growth at the advanced preantral
stage due to the absence of pituitary gonadotropin secre-
tions [9].
Experimental design
Experiment 1: Follicle development was stimulated in all
mice with 20 IU of PMSG (ProSpec-Tany TechnoGene,
Rehovot, Israel) for 3 days. Treatment group animals
(n = 10) were injected intraperitoneally (i.p.) with the
pan-notch inhibitor compound E (KRICT - Korean
Research Institute of Chemical Technology, Daejeon,
Korea) at a dose of 30 μmol/kg animal. Compound E
was suspended finely in 0.5% (w/v) hydroxypropylme-
thylcellulose (Methocel E4M) and 0.1% (w/v) Tween 80
(both Sigma-Aldrich, St. Louis, MO, USA) in water [10].
The compound E was freshly prepared and injected for
5 days starting 2 days prior to the PMSG injection. All
treatment animals were administered Dimethyl sulfoxide
(DMSO) (Sigma-Aldrich, St. Louis, MO, USA) with the
compound E suspension mixed to a total i.p. injection
volume of 170 μL. Control group animals (n = 10) were
injected i.p. with 170 μL DMSO alone. One hour before
sacrifice all animals were injected i.p. with 1 ml 5-bromo-2-
deoxyuridine (BrdU) reagent (Zymed-Invitrogen, Camarillo,
CA USA) per 100 g mouse [9].
Experiment 2: Treatment group animals (n = 5) were
injected with the Genentech anti-Dll4 blocking antibody
(BAb) YW152F (10 mg kg-1) [11] 1 day prior and 1 day
after PMSG administration. The antibodies were diluted
in a total volume of 170 μL DMSO and the solution was
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with human IgG using the same dose and regimen.
Performance of the experiment was otherwise done as
described in experiment 1.
Histology
All animals were sacrificed 5 days after the initiation of
compound E or DMSO treatment and 4 days after anti-
Dll4 BAb YW152F administration. Both ovaries and the
uterus were removed and weighed. Ovaries were embed-
ded in optimal cutting temperature (OCT) medium
(Thermo Fisher Scientific, Waltham, MA, USA), flash
frozen and stored at −80°C. One whole ovary was sec-
tioned serially (12 μm), and each section was stained
with hematoxylin/eosin (H&E) to count the total num-
ber of gonadotropin-dependent preovulatory follicles per
ovary as described previously [9]. Sections of the contra-
lateral ovary (7 μm) of each mouse were used for specific
immunohistochemistry [9]. A piece of small intestine
was flushed gently with cold phosphate buffered saline
(PBS) followed by a flush of formalin. The tissue was
then fixed in formalin at 21°C for 16 h. Intestinal sec-
tions were stained with periodic acid-Shiff (PAS) staining
(Sigma-Aldrich, St. Louis, MO, USA) in order to detect
goblet cells, since Notch γ-secretase inhibition turns
proliferative cells in intestinal crypts into goblet cells
[10]. An increase in the number of goblet cells in the
treatment group over control group served as a positive
control demonstrating that compound E is active. Intestines
from animals of experiment 2 were not stained for goblet
cells as they are not affected by anti-Dll4 antibodies [11].
Blood was obtained through cardiopuncture for the mea-
surement of estradiol (E2) levels as described previously [9].Figure 1 Notch2 (red) in developing follicles. Intense staining in
secondary follicles and sporadic red staining in tertiary follicles
with complete absence of staining in the peripheral theca layer
of the depicted 2 large follicles (10× magnification, DAPI
counterstaining in blue).Immunohistochemistry
The primary antibodies used in these assays were as fol-
lows: goat anti-Notch1 antibody diluted 1/1000, goat
anti-Notch2 diluted 1/500, goat anti-Notch3 antibody
diluted 1/1000, rat anti-Notch4 antibody diluted 1/500,
goat anti-Jagged1 antibody diluted 1/500, goat anti-Dll4
diluted 1/200 (all R&D, Minneapolis, MN, USA), mono-Figure 2 PMSG stimulated untreated ovary with tertiary
follicles: A) Notch3 in red B) PECAM in green C) Composite
image with overlapping areas in yellow. Please note presence of
Notch3 staining in the peripheral theca layer and absence of Notch3
staining on granulosa cells. (10× magnification).
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Biosciences, San Jose, CA, USA), and a mouse anti-alpha
smooth muscle actin antibody diluted 1/200 (VSMC
marker, Sigma-Aldrich, St. Louis, MO, USA). The sec-
ondary anti-goat, anti-rat, anti-mouse 488-alexa and
594-alexa were applied at dilution 1/1000 and finally
mounted with DAPI antibodies (all Sigma-Aldrich, St.
Louis, MO, USA). Immunofluorescence and BrdU staining
(Zymed-Invitrogen, Camarillo, CA USA) was performed
using standard immunohistochemistry and immunofluo-
rescence protocols. [4,9].Data analysis
For each animal, all H&E sections from one ovary were
evaluated to count the total number of preovulatory fol-
licles per ovary as previously described [9]. Statistical
analysis was performed using the Statistical Package for
Social Science version 15 (SPSS, Inc., Chicago, IL, USA).
Data are expressed as mean ± standard error (SE). We
used an unpaired t-test to compare sample means with
statistical significance defined as p < 0.05.Results
Immunofluorescent studies
Notch2 is expressed in GCs of small follicles; Notch3 and
Dll4 are expressed in follicular vasculature.
Using immunofluorescent analysis, we found that
Notch2 is expressed in GCs of secondary follicles and
sporadically in GCs of preovulatory follicles, but is ab-
sent in the peripheral theca layer (Figure 1). Notch3 ex-
pression is largely restricted to VSMCs located in the
theca layer of growing follicles and in interstitial tissue
(Figure 2). No evidence of Notch3 expression was seen
in follicular GCs. The Notch1/Notch4 ligand, Dll4, is
expressed exclusively in ECs in the follicular theca layer
vasculature and ovarian interstitial tissue during the fol-
licular phase (Figure 3). Previously reported vascular ex-
pression patterns of Notch1 (ECs and VSMCs), Notch4Figure 3 Doublestaining of a developing tertiary follicle: A) Dll4 show
showing presence of Dll4 in endothelial cells of the theca vasculature(ECs and VSMCs), and Jagged1 (ECs and VSMCs) [4]
were confirmed (data not shown).
Functional studies
Compound E
The pan-Notch inhibitor, compound E, inhibits gonadotropin-
dependent follicle development to the preovulatory stage.
Administration of the pan-Notch inhibitor, compound
E [12], induced a decrease in the number of follicles ma-
turing to the preovulatory stage when compared to con-
trol after gonadotropin stimulation: control group: 8.5 ±
0.7 (mean ± SEM); treatment group: 3.8 ± 0.8 (p < 0.01)
(Figure 4, Table 1). In addition, the growing follicles in
the treatment group were smaller in size and irregular in
shape (Figure 4). The mean plasma E2 level in the control
group was 83.4 ± 6.5 pg/mL, whereas in the treatment
group it was 29.3 ± 5.2 pg/mL (p < 0.01). Consistent with a
lower number of follicles in the ovaries in the treatment
group, the mean ovarian weight was significantly lower in
the animals treated with compound E (control 5.8 ±
0.8 mg versus treatment 3.5 ± 0.3 mg; p < 0.01). Uterine
weight, reflecting estrogen activity, was also lower in the
treatment group (control 42.9 ± 6.7 mg versus treatment
32.3 ± 2.3 mg; p < 0.05), as shown in Table 1.
Blocking Notch signaling with compound E results in fol-
licular and interstitial tissue blood vessel disorganization
and does not block cell proliferation.
The density of VSMCs expressing alpha-smooth muscle
actin (α-SMA) in the theca layer of follicles and interstitial
tissue of compound E treated animals (Figure 5A-D:
Notch3 and α-SMA) was increased when compared to
control. VSMCs had a very disorganized appearance with
increased vascular thickness when compared to control
(Figure 5A). VSMCs continuity surrounding individual
follicles was often disrupted (Figure 5B). A similar pattern
of disorganization was seen for endothelial cells with an
increase in density in the treatment group when compared
to control (Figure 5E and 5F). Double staining for
PECAM and α-SMA showed mostly an organized patternn in green B) PECAM in red C) composite overlapping images
layer.
Figure 4 Inhibition of Notch signaling with a γ-secretase inhibitor (Compound E) blocked follicle development to the preovulatory
stage. Immunohistochemistry for PECAM (brown) counterstained with hematoxylin. Please note disorganized appearance of PECAM staining in
treatment group. A) three control preovulatory follicles (10× magnification) B) γ-secretase inhibitor treated follicles (10× magnification) C) Enlargement
of treatment follicle in B (20 ×magnification).
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previously [4]. In contrast to the treatment group, many
endothelial cells (green) are devoid of adjacent VSMCs
(Figure 5F). Proliferation of non-GCs, representing most-
ly dividing endothelial cells and VSMCs, was detected
(Figure 6) demonstrating that compound E did not stop
angiogenic proliferation. When comparing proliferation to
the control group, it appears that vascular proliferation
might even be increased in the treatment group (Figure 6),
possibly explaining the increase in vascular density seen in
compound E treated ovaries. Therefore, inhibition of
gonadotropin-dependent follicle growth occurs in a set-
ting of ongoing angiogenesis.
Goblet cells in the intestine are increased in compound
E treated animals.
There was an increase in goblet cells in the intestines
of all compound E treated animals (Figure 7), verifying
that compound E was active.
Dll4 Blocking antibody YW152F
Dll4 Blocking Antibody YW152F does not inhibit
gonadotropin-dependent follicle development to the pre-
ovulatory stage.
Administration of Dll4 BAb YW152F did not cause a
decrease in the number of follicles maturing to the pre-
ovulatory stage when compared to control after gonado-
tropin stimulation: control group: 9.2 ± 0.5 (mean ±
SEM); treatment group: 8.7 ± 0.7 (p > 0.05) (Figure 8).
The mean plasma E2 level in the control group was
78.6 ± 5.4 pg/mL, whereas in the treatment group it wasTable 1 Effect of compound E administration on total
pre-ovulatory follicle number, mean ovarian and uterine
weights and serum estradiol levels when compared to
control animals
Control (n = 10) Treatment (n = 10) P-value
Follicle count 8.5 ± 0.7 3.8 ± 0.8 <0.01
Ovary (mg) 5.8 ± 0.8 3.5 ± 0.3 <0.01
Uterus (mg) 42.9 ± 6.7 32.3 ± 2.3 <0.05
Estradiol (pg/mL) 83.4 ± 6.5 29 ± 5.2 <0.01
Figure 5 Compound E inhibition of Notch signaling increased
vascular smooth muscle cells (VSMC) density and altered VSMC
organization in the ovarian stroma. A-D) Immunofluorescence
staining (10× magnified) for Notch3 (green) and α-SMA (red). C, D)
enlargement of boxes areas in upper panels (20× magnified). Please
note increased thickness and disorganized appearance of VSMCs in
B and D. E, F) PECAM (green) and α-SMA (red). Please note
disorganisation and failure to overlap in F (20× magnified).
Figure 6 Cell proliferation. PECAM (red) and BrdU (green). A) DMSO control treated B) Compound E, (20 × magnification). Please note that
proliferation was not blocked by compound E (B) and even might be increased over control.
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weights were not different between the 2 groups (ovary:
control 6.2 ± 0.7 mg versus treatment 5.5 ± 0.4 mg, p > 0.05;
uterus: control 40.1 ± 5.9 mg versus treatment 38.7 ±
4.4 mg, p > 0.05; Table 2). Analysis of follicular vasculature
demonstrates that integrity is maintained during the treat-
ment, even though it has a slightly disorganized appear-
ance (Figure 8).
Discussion
To understand the possible treatment effects of
interrupting Notch signaling with compound E or an
anti-Dll4 BAb on gonadotropin-dependent folliculoge-
nesis, one has to have a good understanding of where
these molecules are expressed within the follicles. Com-
plementary analysis of the expression of the Notch fam-
ily proteins combined with preexisting data [2,4,5] has
allowed us to obtain a better idea about which type of
cell-to-cell Notch signalling occurs in growing follicles.
We demonstrated that Notch3 is expressed exclusively
in vascular smooth muscle cells (VSMCs), which are ad-
jacent to theca layer endothelial cells [4]. The presence
of Notch3 together with Notch1 [4] on VSMCs suggests
a role in organizing the formation of a mature vascula-
ture. It is very likely to involve interaction with the
Notch ligand Jagged1 [7], which is expressed on ECs and
VSMCs in the theca layer of growing follicles [4]. ItFigure 7 Intestinal section: A) control (DMSO), B) treatment (compoun
cells in B over A (20× magnification).remains unclear as to why we were unable to detect
Notch3 in GCs as described by Johnson et al. [2].
Notch2 was consistently expressed in GCs of preantral
and small antral follicles and sporadic Notch2 staining
was also seen in preovulatory follicles. These findings
suggest that Notch2 in GCs is activated by neighbouring
GCs expressing Jagged2 [2], although we did not specif-
ically stain for this protein. Our findings confirm the
localization noted in in vitro models [3]. Dll4 is exclu-
sively expressed on ECs. Based on previous results [4,5]
and consistent with our data, this suggests that Dll4
expressed on ECs signals to a neighboring EC expressing
Notch1 and possibly Notch4. As Jagged1 is present on
ECs, it might not only signal to VSMCs Notch1/Notch3,
but also compete with Dll4 regarding the interaction
with the Notch1 receptor located on neighboring ECs,
as suggested previously by Benedito [13].
Inhibition of Notch function with the γ-secretase in-
hibitor compound E significantly blocked gonadotropin-
dependent follicle growth up to the preovulatory stage
of development. Thus, the number of follicles evolving
to the preovulatory stage was significantly decreased.
Due to the blockage of gonadotropin-dependent follicle
development, the following secondary effects were seen:
1) lesser degree of increase in ovarian weight due to the
inability to develop tertiary follicles similar in number to
control; 2) lesser degree of increase in uterine weightd E). Goblet cells in red. Please note the increase of intestinal goblet
Figure 8 Control and Dll4 blocking antibody YW152F treated
ovaries stimulated with PMSG (10× magnification).
Doublestaining with PECAM (red) and a-SMA (green). A) Control
ovary. B) YW152F treated ovary. Please note that vascular
appearance is slightly more disorganized in B.
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compared to control. In contrast to the effects of VEGF
receptor 2 (VEGFR-2) BAb on gonadotropin-dependent
folliculogenesis [9], no reduction in follicular or intersti-
tial area blood vessels is seen in ovaries subjected to
compound E. Even though we did not quantify ECs or
VSMCs, our visual inspection suggests that there might
be a slight increase of these cell types in the treatment
group. This supports the finding that vascular cell prolif-
eration continued to occur at least at a level similar to
control in the ovaries from compound E treated animals.
The salient feature of ovarian vasculature exposed to a
γ-secretase inhibitor is its disorganized appearance. One
has the impression that ECs and VSMCs have lost the
ability to connect in an orderly fashion during angio-
genesis. These observations may suggest that compound
E induced perturbation of angiogenesis did not allow
proper assembly of blood vessels.
It is of high interest that disruption of EC signaling
through YW152F, an anti-Dll4 BAb [11] did not disruptTable 2 Effect of Dll4 blocking antibody YW152F on total
pre-ovulatory follicle number, mean ovarian and uterine
weights and serum estradiol levels when compared to
control animals
Control (n = 5) Treatment (n = 5) P-value
Follicle count 9.2 ± 0.5 8.7 ± 0.7 n.s.
Ovary (mg) 6.2 ± 0.7 5.5 ± 0.3 n.s.
Uterus (mg) 40.1 ± 5.9 38.7 ± 4.4 n.s.
Estradiol (pg/mL) 78.6 ± 5.4 69.4 ± 4.9 n.s.
n.s. not significant.follicle growth to the preovulatory stage, nor did it affect
ovarian or uterine weight or E2 production or secretion.
The blocking of EC Notch1 activation seems to cause a
mild level of disorganization of the interaction of ECs
and VSMCs, but it is insufficient to block functional vas-
cular growth and blood circulation to support follicle de-
velopment to the preovulatory stage. In the retina,
YW152F creates a phenotype of non-productive sprou-
ting angiogenesis [11], which is very similar to the effects
seen with γ-secretase inhbitors.
The weakness of our YW152F experiment is that one
could argue that the absence of inhibiting effect on
folliculogenesis in the treated animals might be due to
ineffectiveness of the administered Dll4 BAb. Unlike
with compound E, where the effect can be validated by
observing goblet cell proliferation in the gut, there is no
such readily available positive control for the YW152F
treated animals. However, when administering YW152F
during corpus luteum formation in the same animal
model, there are profound differences in angiogenesis
when Dll4 is blocked [14]. This can indirectly serve as a
proof of action and suggests that different types of an-
giogenic development and growth occur in follicular and
luteal phase, indicating that circular elongation angio-
genesis observed during follicular growth is quite differ-
ent from sprouting angiogenesis in other tissues.
As Notch function is complex, several possibilities
exist to explain our results at the molecular level.Notch and angiogenesis
During inhibition of Notch function, through com-
pound E or YW152F, PMSG driven VEGF production
in GCs is maintained to stimulate vascular growth by
activation of VEGFR-2 on endothelial cells [9,15,16].
Disruption of endothelial Notch1 signaling through
blockage of Dll4 is not sufficient to disrupt coordi-
nation of vascular growth in a significant way. In con-
trast, interference with Notch1 signaling on endothelial
cells, as well as Notch1 and Notch3 signaling on
VSMCs in compound E treated animals disrupts criti-
cal coordination between these 2 cell types, which is
necessary to form mature functional vasculature re-
quired for gonadotropin-dependent follicular growth.
These observations suggest that Notch1 and Notch3
coordinate VEGF driven angiogenesis in the theca layer
during gonadotropin-dependent folliculogenesis.Effects of notch on non-angiogenic cells in the ovary
In-situ hybridization studies demonstrate that Notch2
and Notch3 are expressed on GCs [2]. We did not detect
Notch3 on GCs, but did see Notch2 expressed. Johnson
et al. speculated that GCs Notch activity is necessary for
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licular atresia due to apoptosis. In vitro models have
shown that inhibition of Notch2 leads to reduction of
c-Myc inhibiting granulosa proliferation. Therefore, we
suggest that blockage of Notch2 through administration
of compound E might have affected GCs proliferation
and differentiation, which in turn could have contributed
to the inhibition of follicle development. In this case, the
absence of significant effects observed in YW152F
treated animals would be plausible, since our immuno-
histochemistry stains did not demonstrate presence of
Dll4 or Notch3 within the follicle and blocking this
pathway may have no impact on notch signaling among
granulosa cells. Thus, further experiments with specific
inhibition of Notch2 and Jagged2 are needed.
Conclusions
In summary, we demonstrated by immunohistochemis-
try that members of the Notch family are expressed pri-
marily in the vasculature (except Notch2) of follicles
during folliculogenesis to the preovulatory stage, and
therefore represent a new group of intraovarian regula-
tors. Among intraovarian regulators, Notch is unique as
the ligand and receptor are single-pass transmembrane
proteins, which restricts the Notch pathway to signaling
to neighboring cells [7]. Through functional studies we
demonstrated that compound E, a pan-Notch inhibitor,
but not YW152F, a Dll4 blocking antibody, disrupts the
assembly of theca layer ECs with VSMCs enough to
diminish gonadotropin-dependent follicle growth. It is
meaningful that this type of vascular disturbance is
distinctly different from the non-productive sprouting
angiogenesis seen in the retina when exposed to γ-secretase
inhibitors. It is likely that non-angiogenic Notch2
detected on GCs also plays a role in gonadotropin-
dependent folliculogenesis. Our results represent a prelim-
inary attempt to determine that vascular and possibly
non-vascular Notch play an important role during
gonadotropin-dependent follicle growth to the preovula-
tory stage of development.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
VPJ and CMS carried out all laboratory experiments, analyzed the data and
interpreted the results. VPJ and RCZ drafted the manuscript edited by CMS
and VMS. CJS assisted in data analysis and optimization of
immunohistochemistry. RG performed BrdU staining and assisted in animal
experiments. XW assisted in preparation and administration of Compound E
solution. JK provided material support and participated in design and
coordination. RCZ conceived and implemented the study design. All authors
read and approved the final manuscript.
Acknowledgments
We would like to thank Dr. M. Jan for providing us with the anti-Dll4
YW152F antibody (Genentech, San Francisco, CA).Author details
1Department of Obstetrics and Gynecology, Columbia University Medical
Center, 622 W 168th Street, New York, NY 10032, USA. 2Fertility Center of
Langenhagen and Wolfsburg, Langenhagen 30861, Germany. 3Yale University
School of Medicine, New Haven, Connecticut, USA. 4Fundacion IVI-Instituto
Universitario IVI, INCLIVA, Universidad de Valencia, C/Guadassuar 1 Bajo,
Valencia 46015, Spain.
Received: 4 February 2013 Accepted: 6 May 2013
Published: 15 May 2013
References
1. Palermo R: Differential actions of FSH and LH during folliculogenesis.
Reprod Biomed Online 2007, 15:326–337.
2. Johnson J, Espinoza T, McGaughey RW, Rawls A, Wilson-Rawls J: Notch
pathway genes are expressed in mammalian ovarian follicles. Mech Dev
2001, 109:355–361.
3. Zhang CP, Yang JL, Zhang J, Li L, Huang L, Ji SY, Hu ZY, Gao F, Liu YX:
Notch signaling is involved in ovarian follicle development by regulating
granulosa cell proliferation. Endocrinology 2011, 152:2437–2447.
4. Vorontchikhina MA, Zimmermann RC, Shawber CJ, Tang H, Kitajewski J:
Unique patterns of Notch1, Notch4 and Jagged1 expression in ovarian
vessels during folliculogenesis and corpus luteum formation. Gene Expr
Patterns 2005, 5:701–709.
5. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D: Delta4,
an endothelial specific notch ligand expressed at sites of physiological
and tumor angiogenesis. Differentiation 2001, 69:135–144.
6. Dufraine J, Funahashi Y, Kitajewski J: Notch signaling regulates tumor
angiogenesis by diverse mechanisms. Oncogene 2008, 27:5132–5137.
7. Gridley T: Notch signaling in the vasculature. Curr Top Dev Biol 2010,
92:277–309.
8. Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE, Leek R,
Edelmann M, Kessler B, Sainson RC, et al: New mechanism for Notch
signaling to endothelium at a distance by Delta-like 4 incorporation into
exosomes. Blood 2010, 116:2385–2394.
9. Zimmermann RC, Hartman T, Kavic S, Pauli SA, Bohlen P, Sauer MV,
Kitajewski J: Vascular endothelial growth factor receptor 2-mediated
angiogenesis is essential for gonadotropin-dependent follicle
development. J Clin Invest 2003, 112:659–669.
10. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H,
Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H: Notch/gamma-
secretase inhibition turns proliferative cells in intestinal crypts and
adenomas into goblet cells. Nature 2005, 435:959–963.
11. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J,
Watts RJ, Callahan C, Kasman I, et al: Inhibition of Dll4 signalling
inhibits tumour growth by deregulating angiogenesis. Nature 2006,
444:1083–1087.
12. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M,
Sharma A, Kanamaru E, Borisenko V, Desilva DM, et al: A notch1
ectodomain construct inhibits endothelial notch signaling, tumor
growth, and angiogenesis. Cancer Res 2008, 68:4727–4735.
13. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, Adams RH:
The notch ligands Dll4 and Jagged1 have opposing effects on
angiogenesis. Cell 2009, 137:1124–1135.
14. Fraser HM, Hastings JM, Allan D, Morris KD, Rudge JS, Wiegand SJ:
Inhibition of delta-like ligand 4 induces luteal hypervascularization
followed by functional and structural luteolysis in the primate ovary.
Endocrinology 2012, 153:1972–1983.
15. Fraser HM, Duncan WC: SRB Reproduction, Fertility and Development
Award Lecture 2008. Regulation and manipulation of angiogenesis in
the ovary and endometrium. Reprod Fertil Dev 2009, 21:377–392.
16. Neulen J, Raczek S, Pogorzelski M, Grunwald K, Yeo TK, Dvorak HF, Weich HA,
Breckwoldt M: Secretion of vascular endothelial growth factor/vascular
permeability factor from human luteinized granulosa cells is human chorionic
gonadotrophin dependent. Mol Hum Reprod 1998, 4:203–206.
doi:10.1186/1477-7827-11-43
Cite this article as: Jovanovic et al.: Intraovarian regulation of
gonadotropin-dependent folliculogenesis depends on notch receptor
signaling pathways not involving Delta-like ligand 4 (Dll4). Reproductive
Biology and Endocrinology 2013 11:43.
